The tumor suppressor p53 homologues, TA-p73, and p63 have been shown to function as tumor suppressors. However, how they function as tumor suppressors remains elusive. Expression of p63 is controlled by two distinct promoters. Consequently, this results in two different gene products such as TA-(transactivation domain containing NH2 terminus) p63 and ∆N-(lacks NH2 terminus) p63. It is generally thought that the TA-p63 functions as a tumor suppressor, while the ∆N-p73 functions as a proto-oncogene. However, careful interpretation of the data concerning ∆N-p63 suggests that it could function as an invasion and metastasis/tumor suppressor in a cell context dependent manner.
Background
p53 is a strong tumor suppressor, while its homologues p73, and p63 are fragile tumor suppressors. A number of studies have highlighted the mechanisms by which p53 functions as a tumor suppressor. However, the ability of p73 and p63 to function as tumor suppressors is just beginning to be understood (1) (2) (3) (4) (5) (6) (7) (8) (9) . p63 gene is transcribed from two distinct promoters and it undergoes alternative splicing. Because of which it produces, TA-(transactivation domain containing NH2 terminus) p63 and ∆N-(lacks NH2 terminus) p63. However, the functions of different isoforms of p63 remain abstruse. A number of recent studies hint at a possibility that both TA-p63 and ∆N-p63 could contribute to the inhibition of tumorigenesis in different stages of cancer (2) . Here I discuss this point in detail.
Presentation of the hypothesis
The ability of ∆N-p63 to function as an invasion and metastasis/tumor suppressor in a cell context dependent manner is evident from the following studies.
(1) ∆N-p63 is predominantly expressed in most of the tissues compared to TA-p63 [∆N-p63>TA-p63=p53 (e.g., keratinocytes: ∆Np63 (100): TA-p63/p53 (1) ratio)].
• If N-p63 functions as a dominant negative inhibitor of p53, how does p53 perform its physiological function in the presence of N-p63, especially in keratinocytes where

Np63/p53 ratio is 100:1?(3)
• In response to this question, one may put forth the predominant view that N-p63 suppresses the expression of TA-p63/p53 in response to proliferative signals, while the
TA-p63/p73 suppresses the expression of N-p63 in response to differentiation signals.
• However, this explanation is less convincing considering the fact that over expression of N-p63 induces cell cycle arrest, apoptosis, and senescence in different cell settings (3, (10) (11) (12) .
• Therefore, based on the expression pattern of N-p63 in most of the tissues, one may be tempted to surmise that N-p63 could play a significant role in preventing tumorigenesis/metastasis.
• Although one may be less convinced with this provocative idea from the outset, it is, however, difficult to explain why N-p63 expression is lost in advanced invasive urothelial cancers (3) .
• Based on this data, I argue that ∆N-p63 could function as an invasion and metastasis suppressor.
(2) It has been shown that transgenic expression of ∆N-p63 in keratinocytes results in senescence and aging phenotype (10) , suggesting a possibility that ∆N-p63, by suppressing the expression of SIRT1, it could promote senescence ( Fig. 1) . Over expression of ∆N-p63 in squamous cancer cells also suppresses the expression of SIRT1 (10) . Conversely, increased expression of SIRT1 rescues ∆N-p63-dependent senescence by directly binding to it (10) . However, how ∆N-p63 suppresses SIRT1 or promotes senescence remains elusive. Remarkably, it has been shown that SIRT1 suppresses the expression of the tumor suppressors p53 and TA-p73 (13) (14) (15) (16) , suggesting that ∆N-p63, by suppressing the expression of SIRT1, it could induce the expression of p53 and TA-p73 in skin keratinocytes, and thereby cause senescence (Fig. 1) . Interestingly, p53 has been shown to suppress the expression of SIRT1 through its transcriptional target miRNA, miR-34 (17) , suggesting that ∆N-p63 and p53 may co-operate with each other in the inhibition of SIRT1 expression. Furthermore, SIRT1 has shown to over expressed in a number of cancers and suppresses the expression of the tumor suppressors E-cadherin, GATA-5, MLH1, SFRP1/2, LKB1, Foxo3a, and RB (18) (19) (20) (21) , suggesting that ∆N-p63, by suppressing the expression of SIRT1, it could induce the expression of these tumor/metastasis suppressors and thereby promote senescence (Fig. 1) . This data may also explain why p63+/-/ p73+/-/p73-/-/TAp73-/-/p53+/-/p53-/-mice are prone to tumorigenesis (1; 3). That is, in the absence of p63/p53/p73, SIRT1 expression will be increased. In turn, this could result in suppression of the tumor suppressors p53, p73, p63, E-cadherin, GATA-5, MLH1, SFRP1/2, LKB1, Foxo3a, and RB and promotion of tumorigenesis/metastasis.
(3) SIRT1 has recently been shown to inhibit the expression of miR-134 (22) , suggesting that ∆N-p63, by suppressing the expression of SIRT1, it could increase the expression of miR-134 and thereby decrease its target mRNAs, such as Oct-4, Nanog, LRH-1, Kras, and Sox-2 (8; Target scan) (Fig. 2) . A number of studies suggest that these mRNAs are required for stem cell self-renewal, reprogramming and cancer stem cells (CSCs) proliferation (8), suggesting that ∆N-p63 could suppress stem cell self-renewal, reprogramming, and CSCs proliferation. Further, miR-134 has been predicted to suppress the expression of metastatic initiators, such as collagenease-3 and stromelysin-1 (Target scan), suggesting that ∆N-p63, by suppressing the expression of SIRT1, it could inhibit the expression of collagenease-3 and stromelysin-1, and thereby inhibit invasion and metastasis (Fig. 2) . This data suggests that ∆N-p63 could function as an invasion and metastasis suppressor. Remarkably, it has recently been shown that conditional ablation of IKK-β promotes melanoma development in mice (39) , suggesting that both p53 and ∆N-p63 could inhibit melanoma development ( fig.7) . Another recent study suggests that k-ras induced lung cancer requires NFKB activity (40) , suggesting that both p53 and ∆N-p63 could inhibit lung cancer development by inhibiting NFKB activity through N-myc downstream regulated gene induction. Interestingly, GATA3 has recently been shown to induce the metastasis suppressors E-cadherin, DLC1 (deleted in liver cancer 1), and PAEP (progestagen-associated endometrial protein) and thereby inhibits EMT, breast cancer dissemination and lung metastasis (44) (45) (46) (fig.9 ). This data suggests that ∆N-p63, by inducing the expression of GATA-3, it could increase the expression of E-cadherin, DLC-1, and PAEP, and thereby inhibit invasion and metastasis. Another study suggests that it inhibits tumor progression, motility, and invasivity of adenocarcinoma of the lung (52) . Interestingly, ∆Np63 may also increase claudin1 expression through Ets-1/Runx-3 (53) . Together, these data suggest that ∆Np63, by increasing the expression of claudin-1( fig.11 ), it could function as a metastasis suppressor.
(9) Vitamin D receptor has recently been identified as a transcriptional target of ∆N-p63/p63/p73 (54-55). Remarkably, increased expression of Vitamin D receptor has been shown to increase the expression of the metastasis suppressor E-cadherin (56) . Interestingly, the negative regulator of ∆N-p63 and E-cadherin expression, Snail1 appears to suppress the expression of ∆N-p63/p63/p73's target gene Vitamin D receptor (57) (58) . These data suggest that ∆N-p63, by increasing the expression of Vitamin D receptor ( fig.12) , it could induce E-cadherin expression, and thereby function as a metastasis suppressor.
(10) It has been shown that S100A2 is a transcriptional target of ∆N-p63 (59). Increased expression of S100A2 has been shown to suppress the expression of Cyclooxegenase-2, NFKB2, and EGFR and increase the expression of the tumor suppressor AML2/Runx-3 (60) (fig.13) .
Interestingly, over expression of AML-2 has been shown to increase the expression of p53 and Claudin-1(61). Furthermore, S100A2 has been shown to interact with p53, p73, and p63 and thereby augment the oligomerization property of these proteins (62) . Together, these data suggest that ∆Np63, by increasing the expression of S100A2, it could function as a tumor suppressor.
(11) ∆N-p63 has recently been shown to increase the transcription of ATM and thereby increase the phosphorylation of p53 at Ser-15 (63) (fig.14) . Interestingly, ATM-dependent phosphorylation of p53 at Ser-15 promotes the interaction between p53 and B56γ-specific protein phosphatase 2A (64) . This results in inhibition of proliferation and apoptosis. Further, it has been shown that AML-2/Runx-3 increases the phosphorylation of p53 at ser-15 and thereby functions as a co-activator (65) . As discussed, ∆N-p63 could increase the expression of AML-2/Runx-3 through Ets-1. These data suggest that ∆N-p63, ATM, Runx-3, p53, and B56γ proteins could play a role in response to DNA damage. Unlike ∆N-p63, ∆N-p73 appears to inhibit ATM activation and subsequent phosphorylation of p53 (66) , suggesting that ∆N-p63 could differ from ∆N-p73 in the control of DNA damage response. Interestingly, down regulation of ATM has been shown to inhibit ARF's ability to promote tumor suppression (67) . Together, these data suggest that ∆N-p63, by increasing the expression of ATM, it could promote tumor suppression. 
